
OSE Immunotherapeutics SA
PAR:OSE

OSE Immunotherapeutics SA
Cash Equivalents
OSE Immunotherapeutics SA
Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
![]() |
OSE Immunotherapeutics SA
PAR:OSE
|
Cash Equivalents
€25.9m
|
CAGR 3-Years
-2%
|
CAGR 5-Years
4%
|
CAGR 10-Years
N/A
|
|
![]() |
Valneva SE
PAR:VLA
|
Cash Equivalents
€1k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-64%
|
|
![]() |
Nanobiotix SA
PAR:NANO
|
Cash Equivalents
€66.3m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
9%
|
|
G
|
Genfit SA
PAR:GNFT
|
Cash Equivalents
€53.8m
|
CAGR 3-Years
-15%
|
CAGR 5-Years
-27%
|
CAGR 10-Years
-2%
|
|
![]() |
Inventiva SA
PAR:IVA
|
Cash Equivalents
€8.9m
|
CAGR 3-Years
-53%
|
CAGR 5-Years
-24%
|
CAGR 10-Years
N/A
|
|
![]() |
Eurobio Scientific SA
PAR:ALERS
|
Cash Equivalents
€86.6m
|
CAGR 3-Years
6%
|
CAGR 5-Years
61%
|
CAGR 10-Years
19%
|
OSE Immunotherapeutics SA
Glance View
OSE Immunotherapeutics SA develops immunotherapy products for cancer and auto-immune disease. The company is headquartered in Nantes, Pays De La Loire and currently employs 61 full-time employees. The company went IPO on 2015-03-30. The company develops immunotherapies, directly or through partnerships, for the activation and regulation of the immune system in immuno-oncology and in autoimmune diseases. The firm's research and development in immunology is based on 3 platforms, such as T cell-based vaccines, Immuno-Oncology (myeloid targets) and Auto-Immunity & Inflammation. The company provides technological and scientific platforms: neoepitopes, agonist or antagonist monoclonal antibodies, ideally positioned to fight cancer and autoimmune diseases.

See Also
What is OSE Immunotherapeutics SA's Cash Equivalents?
Cash Equivalents
25.9m
EUR
Based on the financial report for Jun 30, 2024, OSE Immunotherapeutics SA's Cash Equivalents amounts to 25.9m EUR.
What is OSE Immunotherapeutics SA's Cash Equivalents growth rate?
Cash Equivalents CAGR 5Y
4%
Over the last year, the Cash Equivalents growth was 72%. The average annual Cash Equivalents growth rates for OSE Immunotherapeutics SA have been -2% over the past three years , 4% over the past five years .